Navigation Links
A New Mechanism for Tau Protein Pathology in Alzheimer's Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting
Date:11/16/2011

NEW YORK, Nov. 16, 2011 /PRNewswire/ -- Oligomerix, Inc. presented results at the Society for Neuroscience meeting in Washington D.C. which demonstrated that tau protein forms neurotoxic oligomers with a newly discovered enzymatic function. This proteolytic function results in tau's self-fragmentation and in the degradation of other proteins suggesting a mechanism for its neurotoxic mode-of-action. Furthermore, certain tau oligomer species that contained the highest level of activity also proved to be the most toxic to cultured neurons. Tau's enzymatic activity may play a key role in Alzheimer's disease (AD) progression and therefore may represent an important therapeutic intervention point.

James Moe, President and CEO of Oligomerix, Inc., stated, "Recent advances in the field indicate that tau oligomers are involved in Alzheimer's disease progression and inhibit memory formation.  Inhibiting the tau oligomer protease may be an effective intervention for not only improving cognitive function, but also for interrupting disease progression."

The Alzheimer's Association estimates that there are 5.4 million AD sufferers in the US alone that require 14.9 million unpaid caregivers and costs the US economy approximately $183 billion every year.  There are no FDA approved therapeutics that alter the course of disease or slow its progression. Tau protease pathology may represent a new target for slowing or arresting disease progression.

ABOUT OLIGOMERIX

Oligomerix, Inc. is a biopharmaceutical company focused on development of small molecule inhibitors, immunotherapeutic approaches, and biomarkers targeting tau oligomers and their newly discovered proteolytic enzymatic activity.  The Company was founded in 2006 and is located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center.  The Company is seeking strategic partners to help accelerate its exciting tau protease program.

For more information visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.

CONTACTS:
Oligomerix, Inc.
Jack Pasini
Chief Commercial Officer
917-912-4088
jpasini@oligomerix.com

Tiberend Strategic Advisors, Inc.
Andrew Mielach, Media
212-827-0020
amielach@tiberend.com


'/>"/>
SOURCE Oligomerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Scripps Research team discovers treatable mechanism responsible for often deadly response to flu
2. Oxidation mechanisms at gold nanoclusters unraveled
3. New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases
4. Finding a protective mechanism for retinal cells could save sight
5. Scientists use math modeling to predict unknown biological mechanism of regulation
6. Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway
7. Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity
8. Funxional Successfully Completes Initial Clinical Trial of FX125L, an Anti-Inflammatory Drug With a Novel Mechanism of Action
9. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
10. DNA duplication: A mechanism for survival of the fittest
11. New Insights into the Mechanism of Action of Antipsychotic Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... ... LABS, Inc. (LABS) announced in December 2016 that two new Zika Virus ... (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific for IgM and IgG ZIKV antibodies. ... under an Investigational New Drug (IND) study protocol. , Now, as part of ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... EMEA and North America this May on the following dates: ... Donald H. Taylor, Chairman of the Learning and Performance Institute will be the ...
(Date:4/26/2017)... April 26, 2017  Genisphere LLC, provider of ... signed a collaborative and sponsored research agreement with ... Muro . The overall goal of the partnership ... various 3DNA designs and formulations after in ... of the vasculature as well as inflammatory responses, ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... leading supplier of Common Lisp (CL) development tools, and market leader for ... includes key performance enhancements now available within the most effective system for developing ...
Breaking Biology Technology:
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/7/2017)... 7, 2017   HireVue , the leading provider ... identify the best talent, faster, today announced the additions ... (CSO) and Diana Kucer as Chief Marketing ... executive team poised to drive continued growth in the ... year of record bookings in 2017. "Companies ...
Breaking Biology News(10 mins):